Solventum Corporation SOLV
89.50
0.91
1.03%
as of 25 Sep
- Market cap
- $15.1B
- P/E
- 10.9×
Follow SOLV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Solventum Corporation (SOLV) Operating cash flow
Solventum Corporation's operating cash flow for fiscal 2025 was $369.0M, down 68.9% from $1.2B in fiscal 2024. Over the twelve months to 30 June 2026 it was $209.0M. Solventum Corporation ranks 19th of 55 Medical Instruments & Supplies companies by operating cash flow.
Operating cash flow, annual
Annual
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $369.0M | (68.86%) |
| FY2024 | $1.2B | (38.12%) |
| FY2023 | $1.9B | 14.06% |
| FY2022 | $1.7B | — |
Quarterly
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $227.0M | — |
| Mar 2026 | −$189.0M | — |
| Dec 2025 | $95.0M | 25.00% |
| Sep 2025 | $76.0M | (55.03%) |
| 11 more quarters | Free account |
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| ALC Alcon compare | $2.3B |
| BAX Baxter International Inc. compare | $1.3B |
| COO The Cooper Companies, Inc. compare | $1.0B |
| ALGN Align Technology, Inc. compare | $755.7M |
| WST West Pharmaceutical Services, Inc. compare | $662.2M |
| AVTR Avantor, Inc. compare | $597.0M |
| ATR AptarGroup, Inc. compare | $583.5M |
| SOLV Solventum Corporation | $209.0M |
| RGEN Repligen Corporation compare | $134.9M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on SOLV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement